Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function

Michaël J. B. van Baar; Erik J. M. van Bommel; Daan J. Touw; Max Nieuwdorp; Jaap A. Joles; Merle M. Krebber; Petter Bjornstad; Daniël H. van Raalte

doi:https://doi.org/10.1016/j.ekir.2023.01.001

Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function

Michaël J. B. van Baar, Erik J. M. van Bommel, Daan J. Touw, Max Nieuwdorp, Jaap A. Joles, Merle M. Krebber, Petter Bjornstad, Daniël H. van Raalte

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	916-920
Number of pages	5
Journal	Kidney International Reports
Volume	8
Issue number	4
Early online date	2023
DOIs	https://doi.org/10.1016/j.ekir.2023.01.001
Publication status	Published - Apr 2023

Keywords

diabetic kidney disease
glomerular filtration rate
insulin infusion
kidney hemodynamics
kidney perfusion
renal vascular resistance

Access to Document

https://doi.org/10.1016/j.ekir.2023.01.001

Cite this

@article{a9ac370252264f2a8e5f94c2343b40fc,

title = "Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function",

keywords = "diabetic kidney disease, glomerular filtration rate, insulin infusion, kidney hemodynamics, kidney perfusion, renal vascular resistance",

author = "{van Baar}, {Micha{\"e}l J. B.} and {van Bommel}, {Erik J. M.} and Touw, {Daan J.} and Max Nieuwdorp and Joles, {Jaap A.} and Krebber, {Merle M.} and Petter Bjornstad and {van Raalte}, {Dani{\"e}l H.}",

note = "Funding Information: This trial was funded by AstraZeneca as an investigator-initiated study. The funder had no role in the study design, the analyses or interpretation of the data, or drafting the manuscript. The funder had no role in the decision to submit this manuscript for publication. Funding Information: PB reports serving as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, LG Chemistry, Sanofi, Novo Nordisk, and Horizon Pharma. PB also serves on the advisory boards and/or steering committees of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, and XORTX. DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk, Sanofi, and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Novo Nordisk. All honoraria are paid to his employer (Amsterdam UMC, location VUMC). DJT has received research grants from Chiesi Pharmaceutici and acts as consultant for PureIMS and Sanquin. All grants and honoraria are paid to the UMCG. All the other authors declared no competing interests. Funding Information: PB receives salary and research support from National Institute of Diabetes and Digestive and Kidney Diseases ( R01 DK129211 , R01 DK132399 , R21 DK129720 , K23 DK116720 , UC2 DK114886 ), National Heart, Lung, and Blood Institute ( R01 HL165433 ), JDRF (3-SRA-2022-1097-M-B, 3-SRA-2022-1243-M-B, 3-SRA-2022-1230-M-B), Boettcher Foundation , American Heart Association ( 20IPA35260142 ), Ludeman Family Center for Women{\textquoteright}s Health Research at the University of Colorado, the Department of Pediatrics, Section of Endocrinology, and Barbara Davis Center for Diabetes at University of Colorado School of Medicine. MN is supported by a ZONMW VICI grant 2020 (09150182010020).",

year = "2023",

month = apr,

doi = "https://doi.org/10.1016/j.ekir.2023.01.001",

language = "English",

volume = "8",

pages = "916--920",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function

AU - van Baar, Michaël J. B.

AU - van Bommel, Erik J. M.

AU - Touw, Daan J.

AU - Nieuwdorp, Max

AU - Joles, Jaap A.

AU - Krebber, Merle M.

AU - Bjornstad, Petter

AU - van Raalte, Daniël H.

N1 - Funding Information: This trial was funded by AstraZeneca as an investigator-initiated study. The funder had no role in the study design, the analyses or interpretation of the data, or drafting the manuscript. The funder had no role in the decision to submit this manuscript for publication. Funding Information: PB reports serving as a consultant for AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, LG Chemistry, Sanofi, Novo Nordisk, and Horizon Pharma. PB also serves on the advisory boards and/or steering committees of AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk, and XORTX. DHvR has acted as a consultant and received honoraria from Boehringer Ingelheim and Lilly, Merck, Novo Nordisk, Sanofi, and AstraZeneca and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Novo Nordisk. All honoraria are paid to his employer (Amsterdam UMC, location VUMC). DJT has received research grants from Chiesi Pharmaceutici and acts as consultant for PureIMS and Sanquin. All grants and honoraria are paid to the UMCG. All the other authors declared no competing interests. Funding Information: PB receives salary and research support from National Institute of Diabetes and Digestive and Kidney Diseases ( R01 DK129211 , R01 DK132399 , R21 DK129720 , K23 DK116720 , UC2 DK114886 ), National Heart, Lung, and Blood Institute ( R01 HL165433 ), JDRF (3-SRA-2022-1097-M-B, 3-SRA-2022-1243-M-B, 3-SRA-2022-1230-M-B), Boettcher Foundation , American Heart Association ( 20IPA35260142 ), Ludeman Family Center for Women’s Health Research at the University of Colorado, the Department of Pediatrics, Section of Endocrinology, and Barbara Davis Center for Diabetes at University of Colorado School of Medicine. MN is supported by a ZONMW VICI grant 2020 (09150182010020).

PY - 2023/4

Y1 - 2023/4

KW - diabetic kidney disease

KW - glomerular filtration rate

KW - insulin infusion

KW - kidney hemodynamics

KW - kidney perfusion

KW - renal vascular resistance

UR - http://www.scopus.com/inward/record.url?scp=85148747272&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.ekir.2023.01.001

DO - https://doi.org/10.1016/j.ekir.2023.01.001

M3 - Article

C2 - 37069967

SN - 2468-0249

VL - 8

SP - 916

EP - 920

JO - Kidney International Reports

JF - Kidney International Reports

IS - 4

ER -

Acute Effects of Insulin Infusion on Kidney Hemodynamic Function in People With Type 2 Diabetes and Normal Kidney Function

Keywords

Access to Document

Other files and links

Cite this